Noninvasive assessment of liver function

Current Opinion in Gastroenterology

Volumn 31, Issue 3, 2015, Pages 199-208

  Helmke, Steve ^a   Colmenero, Jordi ^b   Everson, Gregory T ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

cholate; chronic liver disease; cirrhosis; disease severity index; hepatic fibrosis; quantitative liver function tests

Indexed keywords

CHOLIC ACID; CHOLIC ACID DERIVATIVE;

CHOLATE TEST; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY ASSESSMENT; DISEASE SEVERITY INDEX; ELASTOGRAPHY; ESOPHAGUS VARICES; FATTY LIVER; FULMINANT HEPATIC FAILURE; GRAFT FAILURE; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER CLEARANCE; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER PERFUSION; LIVER TRANSPLANTATION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; QUANTITATIVE LIVER FUNCTION TEST; REVIEW; HEALTH SERVICE; LIVER; LIVER CELL; LIVER DISEASES; METABOLIC CLEARANCE RATE; METABOLISM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; SEVERITY OF ILLNESS INDEX;

CHOLATES; HEALTH SERVICES NEEDS AND DEMAND; HEPATOCYTES; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; METABOLIC CLEARANCE RATE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84928571625     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000167     Document Type: Review

References (70)

1. Shrestha R, McKinley C, Showalter R, et al. Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. Liver Transpl Surg 1997; 3:166-173.
2. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics. 4th ed. Philadelphia: Pennsylvania: Lippincott Williams & Wilkins; 2010.
3. Stieger B, HegerM, de Graaf W, et al. The emerging role of transport systems in liver function tests. Eur J Pharmacol 2012; 675:1-5.
4. Zeeh J, Lange H, Bosch J, et al. Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology 1988; 95:749-759.
5. Henderson JM, Kutner MH, Bain RP. First-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 1982; 83:1090-1096.
6. Ercolani G, Grazi GL, Calliva R, et al. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. Surgery 2000; 127:464-471.
7. Leevy CM, Bender J. Physiology of dye extraction by the liver: comparative studies of sulfobromophthalein and indocyanine green. Ann NY Acad Sci 1963; 111:161-176.
8. Molino G, Cavanna A, Avagnina P, et al. Hepatic clearance of D-sorbitol. Noninvasive test for evaluating functional liver plasma flow. Dig Dis Sci 1987; 32:753-758.
9. Gilmore IT, Thompson RP. Plasma clearance of oral and intravenous cholic acid in subjects with and without chronic liver disease. Gut 1980; 21:123-127.
10. Vesell ES. Noninvasive assessment in vivo of hepatic drug metabolism in health and disease. Ann NY Acad Sci 1984; 428:293-307.
11. Herold C, Ganslmayer M, Ocker M, et al. Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol 2003; 18:445-449.
12. Klinker H, Joeres R, Bomhard M, et al. Lidocaine elimination and MEGX formation after oral lidocaine administration-a practicable test for assessment of quantitative liver function. Z Gastroenterol 1993; 31 (Suppl 2):52-55.
13. Kawasaki S, Sugiyama Y, Iga T, et al. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. Clin Pharmacol Ther 1988; 44:217-224.
14. Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the hepatitis c antiviral long-term treatment against cirrhosis trial. Hepatology 2012; 55:1019-1029.
15. Jalan R, Hayes PC. Review article: quantitative tests of liver function. Aliment Pharmacol Ther 1995; 9:263-270.
16. Armuzzi A, Candelli M, Zocco MA, et al. Review article: breath testing for human liver function assessment. Aliment Pharmacol Ther 2002; 16:1977-1996.
17. Holzhutter HG, Lock JF, Taheri P, et al. Assessment of hepatic detoxification activity: proposal of an improved variant of the (13)c-methacetin breath test. PLoS One 2013; 8:e70780.
18. Engel G, Hofmann U, Heidemann H, et al. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996; 59:613-623.
19. Afolabi P, WrightM, Wootton SA, Jackson AA. Clinicalutilityof13C-liver-function breath tests for assessment of hepatic function. Dig Dis Sci 2013; 58:33-41.
20. Perri F, Marras RM, Ricciardi R, et al. 13C-breath tests in hepatology (cytosolic liver function). Eur Rev Med Pharmacol Sci 2004; 8:47-49.
21. Grattagliano I, Lauterburg BH, Palasciano G, Portincasa P. 13C-breath tests for clinical investigation of liver mitochondrial function. Eur J Clin Invest 2010; 40:843-850.
22. Dancygier H. Clinical hepatology: principles and practice of hepatobiliary diseases. Berlin and Heidelberg, Germany: Springer-Verlag; 2010.
23. Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007; 24:1803-1823.
24. Everson GT, Martucci MA, Shiffman ML, et al. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther 2007; 26:401-410.
25. Helmke SM, Kulig CC, Lauriski S, et al. Significant alteration of the portal circulation in over half of the chronic HCV patients with Ishak fibrosis stage F0-F2. Hepatology 2011; 54:1328A-1329A.
26. Everson GT, Shiffman ML, Morgan TR, et al. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis trial. Aliment Pharmacol Ther 2008; 27:798-809.
27. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-832.
28. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44:217-231.
29. Helmke SM, DeSanto J, Herman A, et al. A disease severity index based on dual cholate clearances and shunt outperforms biopsy at predicting clinical outcomes in chronic hepatitis C. Gastroenterology 2013; 144:S951-S952.
30. Helmke SM, DeSanto J, Herman A, et al. Alteration of the portal circulation across the entire spectrum of fibrosis in patients with chronic hepatitis C as measured by dual cholate clearances. Hepatology 2012; 56:678A-678A.
31. Helmke S, Wallack A, Herman A, et al. A disease severity index based on dual cholate clearances and shunt identifies primary sclerosing cholangitis waiting list patients at risk for clinical complications. Am J Transplant 2013; 13:513-1513.
32. Helmke SM, Wallack A, Herman A, et al. Slow, moderate, and rapid progressors: three distinct categories of patients with primary sclerosing cholangitis detected by functional assessment using cholate testing. Hepatology 2012; 56:1133A-1133A.
33. Helmke SM, Wallack A, Herman A, et al. Cholate testing is superior to MELD in assessing disease severity in patients with primary sclerosing cholangitis. Liver Transplant 2013; 19:S97-S98.
34. Forestier J, Dumortier J,GuillaudO, et al. Noninvasive diagnosis and prognosis of liver cirrhosis: A comparison of biological scores, elastometry, and metabolic liver function tests. Eur J Gastroenterol Hepatol 2010; 22:532-540.
35. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008; 48 (Suppl 1):S68-S92.
36. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45:797-805.
37. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209-218.
38. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-2618.
39. Crespo G, Fernandez-Varo G, Marino Z, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: A prospective study. J Hepatol 2012; 57:281-287.
40. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
41. Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the noninvasive diagnosis of liver disease. J Hepatol 2014; 60:69-77.
42. Garcia-Pagan JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012; 57:458-461.
43. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133:481-488.
44. Lee YA, Friedman SL. Reversal, maintenance, or progression: what happens to the liver after virologic cure of hepatitis C? Antiviral Res 2014; 107:23-30.
45. Berzigotti A, Reverter E, Garcia-Criado A, et al. Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. J Hepatol 2013; 59:717-722.
46. Annet L, Materne R, Danse E, et al. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003; 229:409-414.
47. Corpechot C, Gaouar F, El Naggar A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014; 146:970-979.
48. Poynard T, Vergniol J, Ngo Y, et al. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTestTM) and transient elastography (FibroScan1). J Hepatol 2014; 60:706-714.
49. Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013; 144:102-111.
50. Colecchia A, Montrone L, Scaioli E, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012; 143:646-654.
51. Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45:1290-1297.
52. Calvaruso V, Burroughs AK, Standish R, et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009; 49:1236-1244.
53. Cross TJS, Calvaruso V, Maimone S, et al. Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat 2010; 17:546-554.
54. Goodman ZD, Stoddard AM, Bonkovsky HL, et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009; 50:1738-1749.
55. Goodman ZD, Becker RL Jr, Pockros PJ, Afdhal NH. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 2007; 45:886-894.
56. Afdhal NH, Bacon BR, Patel K, et al. Accuracy of Fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: A US multicenter study. Clin Gastroenterol Hepatol 2014. [Epub ahead of print] US data on Fibroscan quantification of fibrosis.
57. O'Leary JG, Burton JR, Helmke SM, et al. Early improvement in the HepQuant (HQ)-SHUNT function test during treatment with ledipasvir/sofosbuvir in liver transplant recipients with allograft fibrosis or cirrhosis and patients with decompensated cirrhosis who have not undergone transplantation. Hepatology 2014; 60:1134A.
58. Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther 2009; 29:589-601.
59. Helmke SM, Desanto JL, Herman A, et al. Noninvasive cholate testing predicts response to peginterferon/ribavirin and measures functional improvement after sustained virological response in chronic hepatitis C. J Hepatol 2013; 58:S290-S291.
60. Rincon D, Ripoll C, Iacono OL, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006; 101:2269-2274.
61. Schmidt LE, Ott P, Tygstrup N. Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity: 10 years' experience. Clin Gastroenterol Hepatol 2004; 2:418-424.
62. Merle U, Sieg O, Stremmel W, et al. Sensitivity and specificity of plasma disappearance rate of indocyanine green as a prognostic indicator in acute liver failure. BMC Gastroenterol 2009; 9:91.
63. Potter JM, Hickman PE, Lynch SV, et al. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient. Transplantation 1993; 56:1385-1388.
64. Schutz E, Luy-Kaltefleiter M, Kaltefleiter M, et al. The value of serial determination of MEGX and hyaluronic acid early after orthotopic liver transplantation. Eur J Clin Invest 1996; 26:907-916.
65. Schmidt LE, Rasmussen A, Kirkegaard P, Dalhoff K. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. Transplantation 2003; 76:358-363.
66. Levesque E, Saliba F, Benhamida S, et al. Plasma disappearance rate of indocyanine green: A tool to evaluate early graft outcome after liver transplantation. Liver Transpl 2009; 15:1358-1364.
67. Olmedilla L, Pérez-Peña JM, Ripoll C, et al. Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation. Liver Transpl 2009; 15:1247-1253.
68. Jochum C, Beste M, Penndorf V, et al. Quantitative liver function tests in donors and recipients of living donor liver transplantation. Liver Transpl 2006; 12:544-549.
69. Hori T, Iida T, Yagi S, et al. K(ICG) value, a reliable real-time estimator of graft function, accurately predicts outcomes in adult living-donor liver transplantation. Liver Transpl 2006; 12:605-613.
70. Everson GT, Hoefs JC, Niemann CU, et al. Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy. Liver Transpl 2013; 19:292-304.